SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 24.77+0.7%3:41 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: xomadog2 who wrote (8997)3/8/1999 4:56:00 PM
From: Chris Boylan  Read Replies (2) of 17367
 
> It is also not possible for you to have reason to believe that
> the company does not have statisically sufficient results to
> stop the trial. THE ISSUE FOR THE COMPANY to end the trial IS NOT
> STATISICALLY SUFFICIENT RESULTS.They are in need of having
> enough mortality(deaths) occur in the trial.

What, do you think they are collecting dead kids for fun?
They have that goal for a reason.

> This is not related to the efficacy hurdle that will be looked
> at after the number of minimum events is achieved in this trial.

Wrong. If they have as an end-point reduced morbidity, they need
a certain number of people to die in order to have statistically
valid results if they are going to go before the FDA AC and make
an efficacy claim with regard to morbidity.

I am long on the stock, by the way, and have been for quite awhile.
My hopes for a really big gain have dimmed over the last year unfortunately.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext